Feeding the Wrath with Myelin
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
Kloosterman and colleagues studied molecular and cellular changes during radiation therapy and disease recurrence across molecular subtypes of glioblastoma. They uncovered a distinct immune-cancer cell metabolic crosstalk during proneural/oligodendrocyte progenitor cell-like to mesenchymal-like transition, wherein macrophages feed on cholesterol-rich myelin debris to provide lipids to mesenchymal tumor cells, thereby fueling glioblastoma growth.
References
1.
Lee A, Sun L, Mochizuki A, Reynoso J, Orpilla J, Chow F
. Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nat Commun. 2021; 12(1):6938.
PMC: 8626557.
DOI: 10.1038/s41467-021-26940-2.
View
2.
Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson M
. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110.
PMC: 2818769.
DOI: 10.1016/j.ccr.2009.12.020.
View
3.
Wang J, Cazzato E, Ladewig E, Frattini V, Rosenbloom D, Zairis S
. Clonal evolution of glioblastoma under therapy. Nat Genet. 2016; 48(7):768-76.
PMC: 5627776.
DOI: 10.1038/ng.3590.
View
4.
Schalper K, Rodriguez-Ruiz M, Diez-Valle R, Lopez-Janeiro A, Porciuncula A, Idoate M
. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat Med. 2019; 25(3):470-476.
DOI: 10.1038/s41591-018-0339-5.
View
5.
Cloughesy T, Mochizuki A, Orpilla J, Hugo W, Lee A, Davidson T
. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019; 25(3):477-486.
PMC: 6408961.
DOI: 10.1038/s41591-018-0337-7.
View